A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Christian Dittrich, Prim.Univ.-Prof.
Zentrum für Onkologie und Hämatologie, Kaiser Franz Josef-Spital, Wien, Austria
Principal Investigator - Morten Sorenesen, MD, Ph.D.
The Finsen Center, Department of Oncology, Rigshospitalet, Copenhagen, Denmark
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Prof. Christian Dittrich
Vienna, Austria
- Dr. Morten Soerensen
Copenhagen, Denmark
- Dr. Josep Tabernero
Barcelona, Spain
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2011
- Primary completion
- 31 Mar 2013
- Completion
- 31 Mar 2013
- Last update posted
- 2 Jul 2013
- Registered enrollment
- 16
- Registry id
- NCT01320020
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.